



## COMPANY OVERVIEW

Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. **CDX-101**, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. **CDX-301**, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. Our pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. We also have a commercial business unit that markets ZanthoSyn<sup>®</sup>, a physician recommended astaxanthin dietary supplement for inflammatory health. We sell ZanthoSyn<sup>®</sup> primarily through wholesale and e-commerce channels.

## RECENT NEWS

### Cardax Reports Q1 2021 Results

May 14 2021, 8:00 AM EDT

### Cardax Reports 2020 Results

Apr 15 2021, 8:00 AM EDT

## STOCK OVERVIEW

Symbol	CDXI
Exchange	OTCQB
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

## INVESTOR RELATIONS

Cardax, Inc.  
T: (808) 457-1400  
[investors@cardaxpharma.com](mailto:investors@cardaxpharma.com)

## MANAGEMENT TEAM

**David G. Watumull**  
President and CEO, Director

**David M. Watumull**  
Chief Operating Officer

**Paresh N. Soni, M.D., Ph.D.**  
Chief Clinical and Regulatory Strategist &  
SAB Member

**Gilbert M. Rishton, Ph.D.**  
Chief Science Officer

**Timothy J. King, Ph.D.**  
Vice President, Research

**John B. Russell**  
Chief Financial Officer and Treasurer

## CARDAX, INC.

2800 Woodlawn Drive  
Suite 129  
Honolulu, HI 96822

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.